Efficacy of Heat-Inactivated Hepatitis B Vaccine in Haemodialysis Patients and Staff

Desmyter, Jan; Groote, Guy De; Colaert, J; Reynders, Martin; Reerink-Brongers, E.E.; Dees, P. J.; Lelie, P. N.; Reesink, H. W.

doi:10.1016/s0140-6736(83)91089-9

Cited by 116 publications

(43 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the occupational risk group a seroconversion rate of 70% was obtained, with 60% still positive after one year. This is also lower than in other studies as reported by , who sho wed a 100% seroconversion rate and maintenance of antibody in 98% after a period of one year 9 .…”

Section: Vaccinecontrasting

confidence: 57%

Antibody response to heat-inactivated hepatitis B vaccine (CLB-3mg) in hemodialysis patients and occupational risk personnel: a one year follow-up

Yoshida

Takahashi

Mercadante

et al. 1988

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Immune response against hepatitis B vaccine (CLB 3mg) was evaluated in 59 hemodialysis patients and 20 occupational risk personnel. Seroconversion was induced in 52.5% and 70.0% respectively. Twelve months after the first dose, 37.5% of patients and 60.0% of occupational risk personnel had detectable anti-HBs level. Antibody level was expressed in sample ratio units (SRU). Considering only the responders, in the patients group 38.7% had a low anti-HBs response (2.1-9.9 SRU) 32.3% a medium response (10-99.9 SRU) and 29.0% a high response (>100 SRU) while in occupational risk personnel these values were 14.3%, 64.3% and 21.4% respectively. The authors suggest the use of HBV vaccines with more elevated HBsAg concentration or a reinforced immunization schedule to improve the anti-HBs response not only for patients but also for healthy persons.

show abstract

Section: Vaccinecontrasting

confidence: 57%

Antibody response to heat-inactivated hepatitis B vaccine (CLB-3mg) in hemodialysis patients and occupational risk personnel: a one year follow-up

Yoshida

Takahashi

Mercadante

et al. 1988

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…However, considerable differences between the Pasteur, CLB and MSD vaccines with respect to their efficacies in haemodialysis patients were reported (Desmyter et al, 1983;Desmyter & Colaert, 1984;Stevens et at., 1984b). It is possible that these differences are due to the distinct capacities of these vaccines to elicit anti-preS-specific antibodies.…”

Section: Discussionmentioning

confidence: 99%

Detection of Antiviral Antibodies with Predetermined Specificity Using Synthetic Peptide-beta-Lactamase Conjugates: Application to Antibodies Specific for the preS Region of the Hepatitis B Virus Envelope Proteins

Neurath¹,

Kent²,

Strick³

1986

Journal of General Virology

View full text Add to dashboard Cite

SUMMARYAmino acid sequences coded for by the preS region of the hepatitis B virus (HBV) envelope gene are present both in HBV and in subviral hepatitis B surface antigen (HBsAg) particles. Consequently, anti-preS-specific antibodies are elicited during the course of HBV infection. Such antibodies are virus-neutralizing. Therefore, it is important to determine whether or not vaccination with HBsAg also induces an antipreS-specific immune response. We describe here an enzyme-linked immunosorbent assay applicable for the screening of sera from vaccinated individuals for anti-preS antibodies. IgG from serum specimens was adsorbed to staphylococcal Protein A on a superparamagnetic support and subsequently mixed with a synthetic peptide analogue [preS(120-145)] covalently linked to fl-lactamase. The presence of anti-preS in serum specimens resulted in binding of the conjugated fl-lactamase to the magnetic support. The adsorbed enzyme was quantified colorimetrically.

show abstract

“…Other vaccines, using differ ent methods of purification an d /o r inactivation, have been developed at the Central Laboratory of the Nether lands Red Cross Blood Transfusion Service (CLB) and the lnstitut Pasteur (Pasteur). Studies with these two vaccines in healthy adults have shown a similar percen tage of antibody response against hepatitis B surface antigen (anti-HBs), varying from 90 to 100% [5][6][7]9], In contrast, the antibody response after immunisation with the hepatitis B vaccine in haemodialysis patients is less satisfactory. This group of patients is at high risk for hepatitis B infection and therefore a primary target popu lation forvaccination [10,19].…”

Section: Introductionmentioning

confidence: 99%

Immune Response to Two Different Hepatitis B Vaccines in Haemodialysis Patients: A 2-Year Follow-Up

Graeff

Dankeri

Zeeuw

et al. 1985

Nephron

View full text Add to dashboard Cite

Formalin-inactivated hepatitis B vaccine was given at 0,1 and 6 months to 22 medical staff members and to 37 haemodialysis patients. After vaccination with 20 μg surface antigen (HBsAg), seroconversion occurred in 95% of the staff members. Following immunisation with a double dose, only 74% of the haemodialysis patients developed antibodies against HBsAg (anti-HBs). Anti-HBs levels were lower in the patient group and 6 responders (23%) became anti-HBs-negative within 2 years. 40 other haemodialysis patients were immunised at monthly intervals with either three doses of 3 μg or three doses of 27 μg heat-inactivated hepatitis B vaccine. Seroconversion was achieved in 60% of the patients in the 3-μg group and in 95% of the patients in the 27-μg group. Anti-HBs levels increased significantly when the high dose was used. Although the study design does not allow a definite conclusion, it appears that the immunogenicity per microgramme HBsAg is higher for the heat-inactivated vaccine than for the formalin-inactivated vaccine. The findings further indicate that decreased immune response to hepatitis B vaccination in haemodialysis patients can be improved by increasing the dose of the vaccine. A booster injection should be considered in these patients within 2 years after the first vaccination.

show abstract

Efficacy of Heat-Inactivated Hepatitis B Vaccine in Haemodialysis Patients and Staff

Cited by 116 publications

References 12 publications

Antibody response to heat-inactivated hepatitis B vaccine (CLB-3mg) in hemodialysis patients and occupational risk personnel: a one year follow-up

Antibody response to heat-inactivated hepatitis B vaccine (CLB-3mg) in hemodialysis patients and occupational risk personnel: a one year follow-up

Detection of Antiviral Antibodies with Predetermined Specificity Using Synthetic Peptide-beta-Lactamase Conjugates: Application to Antibodies Specific for the preS Region of the Hepatitis B Virus Envelope Proteins

Immune Response to Two Different Hepatitis B Vaccines in Haemodialysis Patients: A 2-Year Follow-Up

Contact Info

Product

Resources

About